Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26968681 | 0.94 | LMNA (0.54) | ALDH1A1TDP1CYP1A2CYP2A6LMNA | |
| SCHEMBL20076409 | 0.89 | LMNA (0.50) | ALDH1A1TDP1CYP1A2CYP2A6LMNA | |
| SCHEMBL277747 | 0.87 | ELANE (0.52) | ALDH1A1TDP1CYP1A2CYP2A6LMNA | |
| SCHEMBL20285246 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TDP1CYP1A2CYP2A6LMNA | |
| SCHEMBL21125927 | 0.84 | ACHE (0.48) | ALDH1A1TDP1CYP1A2TP53S1PR4 | |
| SCHEMBL24352187 | 0.84 | ALDH1A1 (0.41) | ALDH1A1TDP1CYP1A2CYP2A6LMNA | |
| SCHEMBL10343150 | 0.84 | PLA2G7 (0.47) | ALDH1A1TDP1CYP1A2CYP2A6LMNA | |
| SCHEMBL18171927 | 0.84 | TDP1 (0.58) | ALDH1A1TDP1CYP1A2LMNATP53 | |
| SCHEMBL25488177 | 0.84 | ACHE (0.48) | ALDH1A1TDP1LMNAMAOAMAOB | |
| SCHEMBL15068288 | 0.84 | RAPGEF4 (0.42) | ALDH1A1TDP1CYP1A2CYP2A6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507263-B1 | EFFICIENT CATALYST FOR THE FORMATION OF POLYARYL HYDROCARBONS SUITABLE AS PRECURSORS FOR POLYDENTATE ORGANOPHOSPHORUS CATALYST LIGANDS | EASTMAN CHEM CO (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-2665105-B1 | ORGANIC ELECTROLUMINESCENT ELEMENT, COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, AND ORGANIC ELECTROLUMINESCENT DEVICE | MITSUBISHI CHEM CORP (JP) | 2021-12-01 | — | — | EP | disclosed |
| US-11027977-B2 | Method of manufacturing tantalum carbide material | SHOWA DENKO K.K. (JP) | 2021-06-08 | — | — | US | disclosed |
| EP-2797862-B1 | OLEFIN OLIGOMERIZATION METHODS | CHEVRON PHILLIPS CHEMICAL CO LP (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200198980-A1 | METHOD OF MANUFACTURING TANTALUM CARBIDE MATERIAL | SHOWA DENKO K.K. (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-20090208713-A1 | Trisazo Compounds, Compositions and Ink Jet Printing Processes | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-2024442-A1 | TRISAZO COMPOUNDS, COMPOSITIONS AND INK JET PRINTING PROCESSES | FUJIFILM Imaging Colorants Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| EP-2024443-A1 | TRISAZO DYES, COMPOSITIONS AND INK JET PRINTING PROCESSES | FUJIFILM Imaging Colorants Limited (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20090041939-A1 | Paper, overhead projector slide or printed textile; refillable ink jet printer cartridge | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| WO-2007132151-A1 | TRISAZO DYES, COMPOSITIONS AND INK JET PRINTING PROCESSES | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132150-A1 | TRISAZO COMPOUNDS, COMPOSITIONS AND INK JET PRINTING PROCESSES | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2007-11-22 | — | — | WO | disclosed |
| US-20060111593-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-7041856-B2 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-09 | — | — | US | disclosed |
| US-20030162950-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-28 | — | — | US | disclosed |
| US-3941850-A | ANTIOXIDANT | THE QUAKER OATS COMPANY (US) | 1976-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | ALDH1A1 1263/4885TDP1 3603/4885CYP1A2 686/4885 |
| US-20030162950-A1 | Coupling catalyst and process using the same | NOD1, PYM1, C9 | ALDH1A1 3293/4885TDP1 3316/4885CYP1A2 560/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | ALDH1A1 1282/4885TDP1 3853/4885CYP1A2 718/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | ALDH1A1 1382/4885TDP1 3493/4885CYP1A2 475/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | ALDH1A1 1263/4885TDP1 3603/4885CYP1A2 686/4885 |
| US-20060111593-A1 | Coupling catalyst and process using the same | RPL22, C9, RBM22 | ALDH1A1 3723/4885TDP1 3594/4885CYP1A2 202/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | ALDH1A1 1263/4885TDP1 3603/4885CYP1A2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.